Long-term extension study of ianalumab for lupus nephritis
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study is a follow-up for people with lupus nephritis who already completed a 144-week treatment course with ianalumab in an earlier study. It tests whether continuing or stopping the drug is safe and effective over the long term.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been in the SIRIUS-LN core study and finished the entire 144 weeks of treatment.
- You must agree to take part in this extension study and sign a consent form.
- You cannot be pregnant or currently breastfeeding.
- You cannot be using certain medicines that are not allowed in this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SIM0278 for people with active lupus nephritis (kidney inflammation caused by lupus). It aims to see if adding this drug to standard treatment is safe and helpful for controlling the disease.
This Phase 2 study tests whether LNP023 can improve outcomes and safety in people with active lupus nephritis (lupus-related kidney inflammation), class III or IV. It may help by targeting the ongoing immune activity that is damaging the kidneys.
This trial tests whether adding the drug obinutuzumab to standard therapy (mycophenolate and steroids) helps control lupus-related kidney inflammation better than standard therapy alone. It might reduce kidney damage and improve outcomes for people with active lupus nephritis.
This study looks at whether a specific antibody (anti-alpha-actinin) in the blood is linked to active lupus kidney disease. It may help doctors better understand and monitor kidney problems in people with lupus.
This study tests whether combining two medications, belimumab and voclosporin, is safe and effective for treating a specific type of lupus that affects the kidneys (lupus nephritis). It may help people with active kidney inflammation who need better control of their disease.
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.